ASX:PTX Prescient Therapeutics (PTX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free PTX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume537,831 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield5.88%Price TargetN/A Stock AnalysisStock Analysis Get Prescient Therapeutics alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Prescient Therapeutics Stock (ASX:PTX)Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. PTX Stock News HeadlinesApril 18, 2024 | msn.comPrescient Management Expands Portfolio with Additional PMXINC Securities ListingApril 6, 2024 | msn.comPrescient Management Expands PIPETF Securities in the MarketApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 4, 2024 | msn.comPrescient ETF Expands Offering with Additional Securities ListingMarch 26, 2024 | msn.comPrescient ETF Expands with New Listings in Global Property PortfolioMarch 15, 2024 | msn.comPrescient ETF Expands with New Securities ListingMarch 6, 2024 | finance.yahoo.comWe're Hopeful That Prescient Therapeutics (ASX:PTX) Will Use Its Cash WiselyFebruary 1, 2024 | afr.comPrescient Therapeutics LimitedApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.December 10, 2023 | au.investing.comPrescient Therapeutics’ PTX-100 Phase 1b study shows excellent safety and promising efficacy in T-cell lymphoma patientsNovember 20, 2023 | msn.comMoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunityNovember 16, 2023 | proactiveinvestors.com.auPrescient Therapeutics nearing a potential payday with PTX-100: Pitt Street ResearchNovember 6, 2023 | au.investing.comPrescient Therapeutics to participate in prestigious conference; abstract online nowOctober 31, 2023 | msn.comCancer fighter Prescient navigates challenging conditions for biotech, reports strong Q1 FY24October 17, 2023 | msn.comPrescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conferenceOctober 16, 2023 | proactiveinvestors.com.auPrescient Therapeutics to present clinical data at prestigious US conferenceSeptember 19, 2023 | msn.comASX cancer stocks guide: Here’s everything you need to knowAugust 30, 2023 | msn.com‘Above and beyond approved therapies’: How Prescient Therapeutics is at the forefront of cancer fightingJune 16, 2023 | finance.yahoo.comPrescient Therapeutics showcases cell therapy data at prestigious ISCT conferenceMay 15, 2023 | proactiveinvestors.com.auPrescient Therapeutics to present CellPryme and OmniCAR data to International Society of Cell and Gene TherapyMay 15, 2023 | proactiveinvestors.com.auPrescient Therapeutics bolsters board with appointment of experienced US-based pharma executiveApril 20, 2023 | finance.yahoo.comPrescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth PlansMarch 16, 2023 | proactiveinvestors.com.auPrescient Therapeutics' PTX-100 T Cell Lymphoma Phase 1b trial continues to show promising resultsMarch 15, 2023 | msn.comASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good resultsMarch 9, 2023 | proactiveinvestors.com.auPrescient Therapeutics thrilled with additional Orphan Drug Designation status for PTX-100March 8, 2023 | msn.comGuess which ASX biotech stock just rocketed 29% on big FDA newsMarch 8, 2023 | proactiveinvestors.comPrescient Therapeutics granted US FDA additional Orphan Drug Designation for PTX-100; shares upSee More Headlines Receive PTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prescient Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PTX CUSIPN/A CIKN/A Webwww.ptxtherapeutics.com Phone61 3 9692 7222FaxN/AEmployees171Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,740,000.00 Net Margins-248.74% Pretax MarginN/A Return on Equity-32.67% Return on Assets-20.79% Debt Debt-to-Equity Ratio0.81 Current Ratio10.26 Quick Ratio17.31 Sales & Book Value Annual Sales$3.11 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.91 Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares805,320,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.07 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Steven Lee Yatomi-ClarkeMD, CEO & DirectorMs. Melanie Jaye Leydin B.Bus (Age 51)C.A., CFO & Company Secretary Comp: $158.4kMs. Leanne WestDirector of Clinical Affairs & OperationsDr. Terrence G. Chew (Age 77)Chief Medical Officer Comp: $155.99kMs. Rebecca LimSenior Vice President of Scientific AffairsKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersJames CampbellSold 278,769 sharesTotal: $27,319.36 ($0.10/share) PTX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Prescient Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SkyCity Entertainment Group (SKC) and Findi (FND). This page (ASX:PTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prescient Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
